Zoetis
As on 17 Oct, 2025 | 01:29 IST
| Open | 141.87 |
| Previous Close | 142.12 |
| Beta | 0.02 |
| High | 144.23 |
| Low | 141.17 |
| TTM EPS See historical trend | 6.22(+12.27% YoY) |
| 52 Week High | 195.54 |
| 52 Week Low | 139.37 |
| TTM PE See historical trend | 23.03(Low PE) |
| Mkt. Cap ($ Billion) | 65.58 |
| Dividend Yield | 1.24 |
Advanced Chart
*Delayed by 20 seconds.
MC Technicals
| Days | |
|---|---|
| 5 | 142.44 |
| 10 | 143.38 |
| 20 | 143.8 |
| 50 | 148.65 |
| 100 | 153.62 |
| 200 | 158.01 |
Returns
| 1 Week | -0.09% | |
| 1 Month | -2.86% | |
| 3 Months | -5.35% | |
| YTD | -12.00% | |
| 1 Year | -26.33% | |
| 3 Years | -1.49% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 819.38 | -0.87 | 778.85 | 50.72 | 16.15 | 0.74 | 935.37/623.99 | 7.12 | Very Bullish |
| J&J | 192.13 | 0.50 | 462.99 | 19.21 | 10.00 | 3.29 | 194.24/141.30 | 8.86 | Very Bullish |
| AbbVie | 226.87 | 0.29 | 400.89 | 21.42 | 10.59 | 3.49 | 244.80/163.83 | 4.90 | Bullish |
| Merck | 83.88 | -0.27 | 212.39 | 10.98 | 7.64 | 4.04 | 110.11/73.35 | 3.42 | Neutral |
| Pfizer | 24.23 | -0.66 | 137.20 | 7.15 | 3.39 | 7.07 | 29.48/21.05 | 1.47 | Bearish |
Market news
- Dow, S&P 500 manage record closing highs; Nasdaq falls in volatile sessionOctober 4, 2025 9:34 AM
- Wall Street closes higher, boosted by healthcare as investors shrug off jobs data, US shutdownOctober 2, 2025 8:05 AM
- Wall Street ends streak of weekly gains, yields rise as investors digest dataSeptember 27, 2025 8:50 AM
- Stocks finish week higher; Wall Street at record highsSeptember 20, 2025 7:43 AM
About the company
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.